Hyperbaric oxygen therapy for long COVID (HOT-LoCO), an interim safety report from a randomised controlled trial

With ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common symptoms of PCC, that persists 3 months from the onset of COVID-19 are fatigue, shortness of breath and cognitive dysfunction. No effective treatment options...

Full description

Saved in:
Bibliographic Details
Published inBMC infectious diseases Vol. 23; no. 1; pp. 33 - 8
Main Authors Kjellberg, Anders, Hassler, Adrian, Boström, Emil, El Gharbi, Sara, Al-Ezerjawi, Sarah, Kowalski, Jan, Rodriguez-Wallberg, Kenny A., Bruchfeld, Judith, Ståhlberg, Marcus, Nygren-Bonnier, Malin, Runold, Michael, Lindholm, Peter
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 20.01.2023
BioMed Central
BMC
Subjects
Age
Chronic fatigue syndrome
Clinical medicine
Clinical trial
Clinical trials
Cognitive ability
Compliance
Confidence intervals
Coronaviruses
Cough
COVID-19
COVID-19 - therapy
Double-Blind Method
Health aspects
HRQoL
Humans
Hyperbaric oxygen
Hyperbaric oxygen therapy
Hyperbaric oxygenation
Hyperbaric Oxygenation - adverse effects
Hypoxia
Infectious diseases
Long COVID
Oxygen
Patient outcomes
Patients
Physical tests
Placebos
Post COVID condition
Post-Acute COVID-19 Syndrome
Quality of Life
RCT
Safety
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Treatment Outcome
Sweden
Post COVID condition
RCT
Hyperbaric oxygen
Clinical trial
HRQoL
Safety
Long COVID
HBOT
Online AccessGet full text

Cover

Abstract With ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common symptoms of PCC, that persists 3 months from the onset of COVID-19 are fatigue, shortness of breath and cognitive dysfunction. No effective treatment options have been widely adopted in clinical practice. Hyperbaric oxygen (HBO ) is a candidate drug. The objective of this interim analysis is to describe our cohort and evaluate the safety of HBO for post covid condition. In an ongoing randomised, placebo-controlled, double blind, clinical trial, 20 previously healthy subjects with PCC were assigned to HBO or placebo. Primary endpoints are physical domains in RAND-36; Physical functioning (PF) and Role Physical (RP) at 13 weeks. Secondary endpoints include objective physical tests. Safety endpoints are occurrence, frequency, and seriousness of Adverse Events (AEs). An independent data safety monitoring board (DSMB) reviewed unblinded data. The trial complies with Good Clinical Practice. Safety endpoints are evaluated descriptively. Comparisons against norm data was done using t-test. Twenty subjects were randomised, they had very low HRQoL compared to norm data. Mean (SD) PF 31.75 (19.55) (95% Confidence interval; 22.60-40.90) vs 83.5 (23.9) p < 0.001 in Rand-36 PF and mean 0.00 (0.00) in RP. Very low physical performance compared to norm data. 6MWT 442 (180) (95% CI 358-525) vs 662 (18) meters p < 0.001. 31 AEs occurred in 60% of subjects. In 20 AEs, there were at least a possible relationship with the study drug, most commonly cough and chest pain/discomfort. An (unexpectedly) high frequency of AEs was observed but the DSMB assessed HBO to have a favourable safety profile. Our data may help other researchers in designing trials. Trial Registration ClinicalTrials.gov: NCT04842448. Registered 13 April 2021, https://clinicaltrials.gov/ct2/show/NCT04842448 . EudraCT: 2021-000764-30. Registered 21 May 2021, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000764-30/SE.
AbstractList Abstract Background With ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common symptoms of PCC, that persists 3 months from the onset of COVID-19 are fatigue, shortness of breath and cognitive dysfunction. No effective treatment options have been widely adopted in clinical practice. Hyperbaric oxygen (HBO2) is a candidate drug. Methods The objective of this interim analysis is to describe our cohort and evaluate the safety of HBO2 for post covid condition. In an ongoing randomised, placebo-controlled, double blind, clinical trial, 20 previously healthy subjects with PCC were assigned to HBO2 or placebo. Primary endpoints are physical domains in RAND-36; Physical functioning (PF) and Role Physical (RP) at 13 weeks. Secondary endpoints include objective physical tests. Safety endpoints are occurrence, frequency, and seriousness of Adverse Events (AEs). An independent data safety monitoring board (DSMB) reviewed unblinded data. The trial complies with Good Clinical Practice. Safety endpoints are evaluated descriptively. Comparisons against norm data was done using t-test. Results Twenty subjects were randomised, they had very low HRQoL compared to norm data. Mean (SD) PF 31.75 (19.55) (95% Confidence interval; 22.60–40.90) vs 83.5 (23.9) p < 0.001 in Rand-36 PF and mean 0.00 (0.00) in RP. Very low physical performance compared to norm data. 6MWT 442 (180) (95% CI 358–525) vs 662 (18) meters p < 0.001. 31 AEs occurred in 60% of subjects. In 20 AEs, there were at least a possible relationship with the study drug, most commonly cough and chest pain/discomfort. Conclusions An (unexpectedly) high frequency of AEs was observed but the DSMB assessed HBO2 to have a favourable safety profile. Our data may help other researchers in designing trials. Trial Registration ClinicalTrials.gov: NCT04842448. Registered 13 April 2021, https://clinicaltrials.gov/ct2/show/NCT04842448 . EudraCT: 2021-000764-30. Registered 21 May 2021, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000764-30/SE
BackgroundWith ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common symptoms of PCC, that persists 3 months from the onset of COVID-19 are fatigue, shortness of breath and cognitive dysfunction. No effective treatment options have been widely adopted in clinical practice. Hyperbaric oxygen (HBO2) is a candidate drug.MethodsThe objective of this interim analysis is to describe our cohort and evaluate the safety of HBO2 for post covid condition. In an ongoing randomised, placebo-controlled, double blind, clinical trial, 20 previously healthy subjects with PCC were assigned to HBO2 or placebo. Primary endpoints are physical domains in RAND-36; Physical functioning (PF) and Role Physical (RP) at 13 weeks. Secondary endpoints include objective physical tests. Safety endpoints are occurrence, frequency, and seriousness of Adverse Events (AEs). An independent data safety monitoring board (DSMB) reviewed unblinded data. The trial complies with Good Clinical Practice. Safety endpoints are evaluated descriptively. Comparisons against norm data was done using t-test.ResultsTwenty subjects were randomised, they had very low HRQoL compared to norm data. Mean (SD) PF 31.75 (19.55) (95% Confidence interval; 22.60–40.90) vs 83.5 (23.9) p < 0.001 in Rand-36 PF and mean 0.00 (0.00) in RP. Very low physical performance compared to norm data. 6MWT 442 (180) (95% CI 358–525) vs 662 (18) meters p < 0.001. 31 AEs occurred in 60% of subjects. In 20 AEs, there were at least a possible relationship with the study drug, most commonly cough and chest pain/discomfort.ConclusionsAn (unexpectedly) high frequency of AEs was observed but the DSMB assessed HBO2 to have a favourable safety profile. Our data may help other researchers in designing trials.Trial RegistrationClinicalTrials.gov: NCT04842448. Registered 13 April 2021, https://clinicaltrials.gov/ct2/show/NCT04842448. EudraCT: 2021-000764-30. Registered 21 May 2021, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000764-30/SE
Background With ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common symptoms of PCC, that persists 3 months from the onset of COVID-19 are fatigue, shortness of breath and cognitive dysfunction. No effective treatment options have been widely adopted in clinical practice. Hyperbaric oxygen (HBO.sub.2) is a candidate drug. Methods The objective of this interim analysis is to describe our cohort and evaluate the safety of HBO.sub.2 for post covid condition. In an ongoing randomised, placebo-controlled, double blind, clinical trial, 20 previously healthy subjects with PCC were assigned to HBO.sub.2 or placebo. Primary endpoints are physical domains in RAND-36; Physical functioning (PF) and Role Physical (RP) at 13 weeks. Secondary endpoints include objective physical tests. Safety endpoints are occurrence, frequency, and seriousness of Adverse Events (AEs). An independent data safety monitoring board (DSMB) reviewed unblinded data. The trial complies with Good Clinical Practice. Safety endpoints are evaluated descriptively. Comparisons against norm data was done using t-test. Results Twenty subjects were randomised, they had very low HRQoL compared to norm data. Mean (SD) PF 31.75 (19.55) (95% Confidence interval; 22.60-40.90) vs 83.5 (23.9) p < 0.001 in Rand-36 PF and mean 0.00 (0.00) in RP. Very low physical performance compared to norm data. 6MWT 442 (180) (95% CI 358-525) vs 662 (18) meters p < 0.001. 31 AEs occurred in 60% of subjects. In 20 AEs, there were at least a possible relationship with the study drug, most commonly cough and chest pain/discomfort. Conclusions An (unexpectedly) high frequency of AEs was observed but the DSMB assessed HBO.sub.2 to have a favourable safety profile. Our data may help other researchers in designing trials. Trial Registration ClinicalTrials.gov: NCT04842448. Registered 13 April 2021, Keywords: Long COVID, Post COVID condition, HRQoL, RCT, Clinical trial, Hyperbaric oxygen, HBOT, Safety
With ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common symptoms of PCC, that persists 3 months from the onset of COVID-19 are fatigue, shortness of breath and cognitive dysfunction. No effective treatment options have been widely adopted in clinical practice. Hyperbaric oxygen (HBO.sub.2) is a candidate drug. The objective of this interim analysis is to describe our cohort and evaluate the safety of HBO.sub.2 for post covid condition. In an ongoing randomised, placebo-controlled, double blind, clinical trial, 20 previously healthy subjects with PCC were assigned to HBO.sub.2 or placebo. Primary endpoints are physical domains in RAND-36; Physical functioning (PF) and Role Physical (RP) at 13 weeks. Secondary endpoints include objective physical tests. Safety endpoints are occurrence, frequency, and seriousness of Adverse Events (AEs). An independent data safety monitoring board (DSMB) reviewed unblinded data. The trial complies with Good Clinical Practice. Safety endpoints are evaluated descriptively. Comparisons against norm data was done using t-test. Twenty subjects were randomised, they had very low HRQoL compared to norm data. Mean (SD) PF 31.75 (19.55) (95% Confidence interval; 22.60-40.90) vs 83.5 (23.9) p < 0.001 in Rand-36 PF and mean 0.00 (0.00) in RP. Very low physical performance compared to norm data. 6MWT 442 (180) (95% CI 358-525) vs 662 (18) meters p < 0.001. 31 AEs occurred in 60% of subjects. In 20 AEs, there were at least a possible relationship with the study drug, most commonly cough and chest pain/discomfort. An (unexpectedly) high frequency of AEs was observed but the DSMB assessed HBO.sub.2 to have a favourable safety profile. Our data may help other researchers in designing trials.
With ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common symptoms of PCC, that persists 3 months from the onset of COVID-19 are fatigue, shortness of breath and cognitive dysfunction. No effective treatment options have been widely adopted in clinical practice. Hyperbaric oxygen (HBO2) is a candidate drug.BACKGROUNDWith ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common symptoms of PCC, that persists 3 months from the onset of COVID-19 are fatigue, shortness of breath and cognitive dysfunction. No effective treatment options have been widely adopted in clinical practice. Hyperbaric oxygen (HBO2) is a candidate drug.The objective of this interim analysis is to describe our cohort and evaluate the safety of HBO2 for post covid condition. In an ongoing randomised, placebo-controlled, double blind, clinical trial, 20 previously healthy subjects with PCC were assigned to HBO2 or placebo. Primary endpoints are physical domains in RAND-36; Physical functioning (PF) and Role Physical (RP) at 13 weeks. Secondary endpoints include objective physical tests. Safety endpoints are occurrence, frequency, and seriousness of Adverse Events (AEs). An independent data safety monitoring board (DSMB) reviewed unblinded data. The trial complies with Good Clinical Practice. Safety endpoints are evaluated descriptively. Comparisons against norm data was done using t-test.METHODSThe objective of this interim analysis is to describe our cohort and evaluate the safety of HBO2 for post covid condition. In an ongoing randomised, placebo-controlled, double blind, clinical trial, 20 previously healthy subjects with PCC were assigned to HBO2 or placebo. Primary endpoints are physical domains in RAND-36; Physical functioning (PF) and Role Physical (RP) at 13 weeks. Secondary endpoints include objective physical tests. Safety endpoints are occurrence, frequency, and seriousness of Adverse Events (AEs). An independent data safety monitoring board (DSMB) reviewed unblinded data. The trial complies with Good Clinical Practice. Safety endpoints are evaluated descriptively. Comparisons against norm data was done using t-test.Twenty subjects were randomised, they had very low HRQoL compared to norm data. Mean (SD) PF 31.75 (19.55) (95% Confidence interval; 22.60-40.90) vs 83.5 (23.9) p < 0.001 in Rand-36 PF and mean 0.00 (0.00) in RP. Very low physical performance compared to norm data. 6MWT 442 (180) (95% CI 358-525) vs 662 (18) meters p < 0.001. 31 AEs occurred in 60% of subjects. In 20 AEs, there were at least a possible relationship with the study drug, most commonly cough and chest pain/discomfort.RESULTSTwenty subjects were randomised, they had very low HRQoL compared to norm data. Mean (SD) PF 31.75 (19.55) (95% Confidence interval; 22.60-40.90) vs 83.5 (23.9) p < 0.001 in Rand-36 PF and mean 0.00 (0.00) in RP. Very low physical performance compared to norm data. 6MWT 442 (180) (95% CI 358-525) vs 662 (18) meters p < 0.001. 31 AEs occurred in 60% of subjects. In 20 AEs, there were at least a possible relationship with the study drug, most commonly cough and chest pain/discomfort.An (unexpectedly) high frequency of AEs was observed but the DSMB assessed HBO2 to have a favourable safety profile. Our data may help other researchers in designing trials. Trial Registration ClinicalTrials.gov: NCT04842448. Registered 13 April 2021, https://clinicaltrials.gov/ct2/show/NCT04842448 . EudraCT: 2021-000764-30. Registered 21 May 2021, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000764-30/SE.CONCLUSIONSAn (unexpectedly) high frequency of AEs was observed but the DSMB assessed HBO2 to have a favourable safety profile. Our data may help other researchers in designing trials. Trial Registration ClinicalTrials.gov: NCT04842448. Registered 13 April 2021, https://clinicaltrials.gov/ct2/show/NCT04842448 . EudraCT: 2021-000764-30. Registered 21 May 2021, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000764-30/SE.
With ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common symptoms of PCC, that persists 3 months from the onset of COVID-19 are fatigue, shortness of breath and cognitive dysfunction. No effective treatment options have been widely adopted in clinical practice. Hyperbaric oxygen (HBO ) is a candidate drug. The objective of this interim analysis is to describe our cohort and evaluate the safety of HBO for post covid condition. In an ongoing randomised, placebo-controlled, double blind, clinical trial, 20 previously healthy subjects with PCC were assigned to HBO or placebo. Primary endpoints are physical domains in RAND-36; Physical functioning (PF) and Role Physical (RP) at 13 weeks. Secondary endpoints include objective physical tests. Safety endpoints are occurrence, frequency, and seriousness of Adverse Events (AEs). An independent data safety monitoring board (DSMB) reviewed unblinded data. The trial complies with Good Clinical Practice. Safety endpoints are evaluated descriptively. Comparisons against norm data was done using t-test. Twenty subjects were randomised, they had very low HRQoL compared to norm data. Mean (SD) PF 31.75 (19.55) (95% Confidence interval; 22.60-40.90) vs 83.5 (23.9) p < 0.001 in Rand-36 PF and mean 0.00 (0.00) in RP. Very low physical performance compared to norm data. 6MWT 442 (180) (95% CI 358-525) vs 662 (18) meters p < 0.001. 31 AEs occurred in 60% of subjects. In 20 AEs, there were at least a possible relationship with the study drug, most commonly cough and chest pain/discomfort. An (unexpectedly) high frequency of AEs was observed but the DSMB assessed HBO to have a favourable safety profile. Our data may help other researchers in designing trials. Trial Registration ClinicalTrials.gov: NCT04842448. Registered 13 April 2021, https://clinicaltrials.gov/ct2/show/NCT04842448 . EudraCT: 2021-000764-30. Registered 21 May 2021, https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-000764-30/SE.
ArticleNumber 33
Audience Academic
Author Ståhlberg, Marcus
El Gharbi, Sara
Al-Ezerjawi, Sarah
Kowalski, Jan
Boström, Emil
Hassler, Adrian
Runold, Michael
Bruchfeld, Judith
Nygren-Bonnier, Malin
Rodriguez-Wallberg, Kenny A.
Lindholm, Peter
Kjellberg, Anders
Author_xml – sequence: 1
  givenname: Anders
  orcidid: 0000-0002-4819-1024
  surname: Kjellberg
  fullname: Kjellberg, Anders
– sequence: 2
  givenname: Adrian
  orcidid: 0000-0002-5796-1801
  surname: Hassler
  fullname: Hassler, Adrian
– sequence: 3
  givenname: Emil
  orcidid: 0000-0001-6922-7631
  surname: Boström
  fullname: Boström, Emil
– sequence: 4
  givenname: Sara
  orcidid: 0000-0002-0632-1839
  surname: El Gharbi
  fullname: El Gharbi, Sara
– sequence: 5
  givenname: Sarah
  orcidid: 0000-0002-5940-6182
  surname: Al-Ezerjawi
  fullname: Al-Ezerjawi, Sarah
– sequence: 6
  givenname: Jan
  orcidid: 0000-0001-5414-6556
  surname: Kowalski
  fullname: Kowalski, Jan
– sequence: 7
  givenname: Kenny A.
  orcidid: 0000-0003-4378-6181
  surname: Rodriguez-Wallberg
  fullname: Rodriguez-Wallberg, Kenny A.
– sequence: 8
  givenname: Judith
  orcidid: 0000-0001-5399-0982
  surname: Bruchfeld
  fullname: Bruchfeld, Judith
– sequence: 9
  givenname: Marcus
  orcidid: 0000-0003-0319-6240
  surname: Ståhlberg
  fullname: Ståhlberg, Marcus
– sequence: 10
  givenname: Malin
  orcidid: 0000-0001-6731-8468
  surname: Nygren-Bonnier
  fullname: Nygren-Bonnier, Malin
– sequence: 11
  givenname: Michael
  orcidid: 0000-0001-7568-2278
  surname: Runold
  fullname: Runold, Michael
– sequence: 12
  givenname: Peter
  orcidid: 0000-0002-0840-9244
  surname: Lindholm
  fullname: Lindholm, Peter
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36670365$$D View this record in MEDLINE/PubMed
BookMark eNqNkltr2zAYhs3oWA_bH9jFEOymhbnTwZbkm0HJDg0EAlvXW_HZllwFR_JkZTT_fnLTdU0ZYxZYQnq-V9Kr9zg7cN7pLHtN8Dkhkr8fCZWiyjFlOZYY01w-y45IIUhOGSsOHo0Ps-NxXGFMhKTVi-yQcS4w4-VRNlxuBx1qCLZB_nbbaYfijQ4wbJHxAfXedWi2vJ5_RKeXy6t84WfLs3cIHLIu6mDXaASj4xYFPfgQkQl-jQAFcK1f21G3qPEuBt_3aRiDhf5l9txAP-pX9_1J9v3zp6vZZb5YfpnPLhZ5w3kVcyMqLGTJ049BBRgzVhVAWi5KwzGjRADDpimoELgtC0PLWhBT01q3gKUBdpLNd7qth5Ua0lEhbJUHq-4mfOgUhGibXitdEhC4kpiBLLg2NWhDtSFpDyjqatL6sNMaNvVat41OV4J-T3R_xdkb1fmfqpJlgYVIAqf3AsH_2OgxqmROo_senPabUVHBJS0KXk3o2yfoym-CS1YlKn28qIj8Q3WQLmCd8WnfZhJVF4IVmFKOSaLO_0Kl1uq1TQ-jjU3zewVnewXT4-nb2MFmHNX829f_Z5fX--ybxwY-OPc7hwmgO6AJfhyDNg8IwWoKu9qFXaWwq7uwq8kE-aSosRGinRIHtv9X6S8Mev75
CitedBy_id crossref_primary_10_3389_fmed_2024_1354088
crossref_primary_10_1136_bmjopen_2024_085272
crossref_primary_10_1016_j_rmed_2023_107155
crossref_primary_10_1016_j_pupt_2024_102330
crossref_primary_10_7759_cureus_67603
crossref_primary_10_1097_SHK_0000000000002287
crossref_primary_10_1080_14737175_2024_2440543
crossref_primary_10_12677_ACM_2023_1391945
crossref_primary_10_4103_mgr_MEDGASRES_D_24_00044
crossref_primary_10_1136_bmjopen_2024_083868
crossref_primary_10_3389_fmed_2024_1263511
crossref_primary_10_3390_life14040438
crossref_primary_10_1002_tre_939
crossref_primary_10_1007_s00406_024_01911_y
crossref_primary_10_1007_s11596_023_2799_1
crossref_primary_10_3390_metabo13101032
Cites_doi 10.1038/s41598-022-15565-0
10.1186/s41687-021-00331-z
10.1136/bmjopen-2022-061870
10.1136/bmj.n136
10.1016/S1473-3099(21)00703-9
10.3390/biom10060958
10.1016/S0140-6736(21)02798-7
10.1186/1741-7015-8-18
10.1038/s41591-021-01283-z
10.7861/clinmed.2021-0462
10.1002/jmv.27309
10.1038/s41590-021-01104-y
10.1371/journal.pone.0127012
10.1016/j.mehy.2020.110224
10.1186/s13256-022-03287-w
10.1002/ehf2.12633
10.1177/1740774518776952
10.1001/jama.2017.21903
10.1016/j.apmr.2014.02.016
ContentType Journal Article
Copyright 2023. The Author(s).
COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2023
Copyright_xml – notice: 2023. The Author(s).
– notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2023
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
IOV
ISR
3V.
7QL
7T2
7U9
7X7
7XB
88E
8C1
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BENPR
C1K
CCPQU
COVID
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
M7N
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s12879-023-08002-8
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Opposing Viewpoints (Gale in Context)
Gale In Context: Science
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Health and Safety Science Abstracts (Full archive)
Virology and AIDS Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability (subscription)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
Environmental Sciences and Pollution Management
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
Environmental Sciences and Pollution Management
ProQuest Central
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
AIDS and Cancer Research Abstracts
Health & Safety Science Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Public Health
Virology and AIDS Abstracts
ProQuest One Academic Eastern Edition
Coronavirus Research Database
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database



MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1471-2334
EndPage 8
ExternalDocumentID oai_doaj_org_article_e51a709803a846efbaef2ef117aa4b9a
PMC9854077
A734022601
36670365
10_1186_s12879_023_08002_8
Genre Randomized Controlled Trial
Journal Article
GeographicLocations Sweden
GeographicLocations_xml – name: Sweden
GrantInformation_xml – fundername: ;
GroupedDBID ---
0R~
23N
2WC
53G
5VS
6J9
6PF
7X7
88E
8C1
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
ADUKV
AEAQA
AENEX
AEUYN
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAD
EAP
EAS
EBD
EBLON
EBS
EMB
EMK
EMOBN
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
IOV
ISR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
SV3
TR2
TUS
UKHRP
W2D
WOQ
WOW
XSB
-A0
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7QL
7T2
7U9
7XB
8FK
AZQEC
C1K
COVID
DWQXO
H94
K9.
M7N
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c669t-f79078560783a9a003394a1d675f603217a30fc42770d54f25b71fb2beda08fa3
IEDL.DBID M48
ISSN 1471-2334
IngestDate Wed Aug 27 01:32:24 EDT 2025
Thu Aug 21 18:38:48 EDT 2025
Fri Jul 11 00:16:04 EDT 2025
Fri Jul 25 23:02:28 EDT 2025
Tue Jun 17 20:57:49 EDT 2025
Tue Jun 10 20:13:23 EDT 2025
Fri Jun 27 06:02:24 EDT 2025
Fri Jun 27 06:09:07 EDT 2025
Thu Jan 02 22:52:46 EST 2025
Tue Jul 01 03:10:41 EDT 2025
Thu Apr 24 23:03:29 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Post COVID condition
RCT
Hyperbaric oxygen
Clinical trial
HRQoL
Safety
Long COVID
HBOT
Language English
License 2023. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c669t-f79078560783a9a003394a1d675f603217a30fc42770d54f25b71fb2beda08fa3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Undefined-1
content type line 23
ORCID 0000-0001-6922-7631
0000-0001-5414-6556
0000-0001-7568-2278
0000-0002-0632-1839
0000-0001-6731-8468
0000-0002-5796-1801
0000-0002-5940-6182
0000-0002-4819-1024
0000-0003-4378-6181
0000-0003-0319-6240
0000-0002-0840-9244
0000-0001-5399-0982
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12879-023-08002-8
PMID 36670365
PQID 2777764918
PQPubID 42582
PageCount 8
ParticipantIDs doaj_primary_oai_doaj_org_article_e51a709803a846efbaef2ef117aa4b9a
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9854077
proquest_miscellaneous_2768244697
proquest_journals_2777764918
gale_infotracmisc_A734022601
gale_infotracacademiconefile_A734022601
gale_incontextgauss_ISR_A734022601
gale_incontextgauss_IOV_A734022601
pubmed_primary_36670365
crossref_primary_10_1186_s12879_023_08002_8
crossref_citationtrail_10_1186_s12879_023_08002_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-01-20
PublicationDateYYYYMMDD 2023-01-20
PublicationDate_xml – month: 01
  year: 2023
  text: 2023-01-20
  day: 20
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle BMC infectious diseases
PublicationTitleAlternate BMC Infect Dis
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References K Brown (8002_CR5) 2022; 399
S Zilberman-Itskovich (8002_CR11) 2022; 12
A Hadanny (8002_CR13) 2020; 10
E Ohlsson-Nevo (8002_CR19) 2021; 5
P Malik (8002_CR21) 2022; 94
S Efrati (8002_CR6) 2015; 10
S Mehandru (8002_CR4) 2022; 23
N Scherbakov (8002_CR20) 2020; 7
S Akarsu (8002_CR7) 2013; 40
T Robbins (8002_CR9) 2021; 21
M Calvert (8002_CR16) 2018; 319
A Kjellberg (8002_CR10) 2022; 12
A Kjellberg (8002_CR12) 2020; 144
JB Soriano (8002_CR2) 2021; 22
W Shah (8002_CR3) 2021; 372
A Nalbandian (8002_CR1) 2021; 27
AT Tveter (8002_CR18) 2014; 95
KF Schulz (8002_CR15) 2010; 8
CA Lansdorp (8002_CR17) 2018; 15
AM Bhaiyat (8002_CR8) 2022; 16
8002_CR14
References_xml – volume: 12
  start-page: 11252
  issue: 1
  year: 2022
  ident: 8002_CR11
  publication-title: Sci Rep
  doi: 10.1038/s41598-022-15565-0
– volume: 5
  start-page: 66
  issue: 1
  year: 2021
  ident: 8002_CR19
  publication-title: J Patient Rep Outcomes
  doi: 10.1186/s41687-021-00331-z
– volume: 12
  issue: 11
  year: 2022
  ident: 8002_CR10
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2022-061870
– volume: 372
  year: 2021
  ident: 8002_CR3
  publication-title: BMJ
  doi: 10.1136/bmj.n136
– volume: 22
  start-page: e102
  year: 2021
  ident: 8002_CR2
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(21)00703-9
– volume: 10
  start-page: 958
  issue: 6
  year: 2020
  ident: 8002_CR13
  publication-title: Biomolecules
  doi: 10.3390/biom10060958
– volume: 399
  start-page: 355
  issue: 10322
  year: 2022
  ident: 8002_CR5
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)02798-7
– volume: 40
  start-page: 197
  issue: 2
  year: 2013
  ident: 8002_CR7
  publication-title: Undersea Hyperb Med
– volume: 8
  start-page: 18
  year: 2010
  ident: 8002_CR15
  publication-title: BMC Med
  doi: 10.1186/1741-7015-8-18
– volume: 27
  start-page: 601
  issue: 4
  year: 2021
  ident: 8002_CR1
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01283-z
– volume: 21
  start-page: e629
  issue: 6
  year: 2021
  ident: 8002_CR9
  publication-title: Clin Med (Lond)
  doi: 10.7861/clinmed.2021-0462
– ident: 8002_CR14
– volume: 94
  start-page: 253
  issue: 1
  year: 2022
  ident: 8002_CR21
  publication-title: J Med Virol
  doi: 10.1002/jmv.27309
– volume: 23
  start-page: 194
  issue: 2
  year: 2022
  ident: 8002_CR4
  publication-title: Nat Immunol
  doi: 10.1038/s41590-021-01104-y
– volume: 10
  issue: 5
  year: 2015
  ident: 8002_CR6
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0127012
– volume: 144
  start-page: 110224
  year: 2020
  ident: 8002_CR12
  publication-title: Med Hypotheses
  doi: 10.1016/j.mehy.2020.110224
– volume: 16
  start-page: 80
  issue: 1
  year: 2022
  ident: 8002_CR8
  publication-title: J Med Case Rep
  doi: 10.1186/s13256-022-03287-w
– volume: 7
  start-page: 1064
  issue: 3
  year: 2020
  ident: 8002_CR20
  publication-title: ESC Heart Fail
  doi: 10.1002/ehf2.12633
– volume: 15
  start-page: 462
  issue: 5
  year: 2018
  ident: 8002_CR17
  publication-title: Clin Trials
  doi: 10.1177/1740774518776952
– volume: 319
  start-page: 483
  issue: 5
  year: 2018
  ident: 8002_CR16
  publication-title: JAMA
  doi: 10.1001/jama.2017.21903
– volume: 95
  start-page: 1366
  issue: 7
  year: 2014
  ident: 8002_CR18
  publication-title: Arch Phys Med Rehabil
  doi: 10.1016/j.apmr.2014.02.016
SSID ssj0017829
Score 2.4517245
Snippet With ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common symptoms of PCC,...
Background With ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common...
BackgroundWith ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem. Common...
Abstract Background With ~ 50 million individuals suffering from post-COVID condition (PCC), low health related quality of life (HRQoL) is a vast problem....
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 33
SubjectTerms Age
Chronic fatigue syndrome
Clinical medicine
Clinical trial
Clinical trials
Cognitive ability
Compliance
Confidence intervals
Coronaviruses
Cough
COVID-19
COVID-19 - therapy
Double-Blind Method
Health aspects
HRQoL
Humans
Hyperbaric oxygen
Hyperbaric oxygen therapy
Hyperbaric oxygenation
Hyperbaric Oxygenation - adverse effects
Hypoxia
Infectious diseases
Long COVID
Oxygen
Patient outcomes
Patients
Physical tests
Placebos
Post COVID condition
Post-Acute COVID-19 Syndrome
Quality of Life
RCT
Safety
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Treatment Outcome
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELfQHhAvCMZXx4YMQgIE1pLY8cfjKEwdYlSCbdqbZTv2qFSSaWkl-t9zdtKqEQJeeIviX6T47uK7i8-_Q-hlZoVxhYfchAlHWKU4Mb5kRMrgHGU0OBt_DZx-4ZNz9umyvNxq9RVrwjp64E5wh77MjciUzKgBV-mDNT4UPuS5MIZZlUIj8HnrZKrfPwC_p9ZHZCQ_bGEVFoqAfyIpQiJy4IYSW__va_KWUxoWTG55oON76G4fOuKj7pXvo1u-3kW3T_vN8QfoegI5Zdw9mDnc_FyBZeDudNUKQ2SK5019hcfTi5MP-PVkekY-N-Ppm3fY1DhSRtzMfuDWBL9Y4W4bAceDJ9hg8GVVA8bgK9yXtc_hMjX7eIjOjz-ejSekb6hAHOdqQYKAVFhCjCMkNcrEPm6KmbyCpCHwjEJ2YmgWHCuEyKqShaK0Ig-2sL4ymQyGPkI7dVP7JwhTZXNpARok-DfKJK0qy5RxpZNVwcUI5Wv5atezjcemF3Odsg7JdacTDTrRSSdajtDbzTPXHdfGX9Hvo9o2yMiTnW6A9ejeevS_rGeEXkSl68iEUcdSmyuzbFt9Mr3QRzArCHAgYf0T6NvXAehVDwoNTNSZ_ngDiCsybA2Q-wMkqNANh9cGqPv1pNWgESE4UzlM-_lmOD4Za-Rq3ywjhksI1rgC4T_u7HUjHMp5ZForR0gMLHkgveFIPfue2MaVjByNYu9_iPspulOkjzCH1Xkf7Sxulv4AgrqFfZa-31-TaEdU
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3rixMxEA96gvhFfF_1lCiCiobbRzaPT3JWj554FvTu6LeQZJNaqLu124L9753spvUW8fZT2cxCMzOZRzL5DUIvE8O1zRzkJpRbQkvJiHYFJUJ4a3Oae2vC1sDpVzY6p58nxSRuuDWxrHJrE1tDXdY27JEfZhweRmUq3i9-kdA1KpyuxhYa19GNAF0WtJpPdglXCt5Pbi_KCHbYgC3mkoCXIm2cRETPGbWY_f9a5kuuqV82eckPHd9Bt2MAiY86id9F11x1D908jUfk99FiBJllOEOYWVz_3oB-4O6O1QZDfIrndTXFw_HFyUf8ejQ-I1_q4fjNO6wrHIAjlrOfuNHerTa4O0zA4foJ1hg8WlmDSrgSx-L2OfxsW348QOfHn86GIxLbKhDLmFwRzyEhFhDpcJFrqUM3N0l1WkLq4FmSQ46i88RbChxPyoL6rDA89SYzrtSJ8Dp_iPaqunL7COfSpMIAqRfg5XIq8rI0VGpbWFFmjA9QuuWvshFzPLS-mKs29xBMdTJRIBPVykSJAXq7-2bRIW5cSf0hiG1HGdCy2xf1cqri4lOuSDVPpEhyDeGW80Y7nzmfwkw1NVIP0IsgdBXwMKpQcDPV66ZRJ-MLdQSzgjAH0tb_EX3_1iN6FYl8DRO1Ol5yAHYFnK0e5UGPEkRo-8NbBVTRqjTq7xoYoOe74fBlqJSrXL0ONExAyMYkMP9Rp6875uSMBby1YoB4T5N73OuPVLMfLea4FAGpkT---m89QbeydnmlYH0P0N5quXZPIWhbmWftyvwD0mU9zg
  priority: 102
  providerName: ProQuest
Title Hyperbaric oxygen therapy for long COVID (HOT-LoCO), an interim safety report from a randomised controlled trial
URI https://www.ncbi.nlm.nih.gov/pubmed/36670365
https://www.proquest.com/docview/2777764918
https://www.proquest.com/docview/2768244697
https://pubmed.ncbi.nlm.nih.gov/PMC9854077
https://doaj.org/article/e51a709803a846efbaef2ef117aa4b9a
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3rb9MwELf2kBBfEG8KozIICRAEktjx4wNCa9nUIbqisU7VvliOY5dKJRl9SOt_zzlJyyIG4ksUxZdEvkfuLvb9DqEXYcq1iS3kJpSbgGaSBdomNBDCGUMocSb1vwb6x6w3pJ9HyWgLrdsd1QycX5va-X5Sw9n03eXP1Ucw-A-lwQv2fg7fWC4D8D5BGf8EYhvtgmfivqNBn_5eVQBvKMtqIx4FMSF0XURz7TMajqrE8__zq33FbTW3VF7xUYe30a06uMT7lTbcQVs2v4tu9Ovl83voogdZp19fmBhcXK5Ad3BVf7XCELviaZGPcXdwdvQJv-oNToMvRXfw-i3WOfagErPJDzzXzi5WuFpowL40BWsM3i4rQF1shuuN71M4LduB3EfDw4PTbi-oWy4EhjG5CByHZFlAFMQF0VL7Tm-S6iiDtMKxkED-oknoDI05D7OEujhJeeTSOLWZDoXT5AHayYvcPkKYyDQSKZA6AR6QUEGyLKVSm8SILGa8haI1f5Wp8ch9W4ypKvMSwVQlEwUyUaVMlGihN5t7Lio0jn9Sd7zYNpQeSbu8UMzGqjZMZZNI81CKkGgIxaxLtXWxdRHMVNNU6hZ67oWuPFZG7jfjjPVyPldHgzO1D7OCEAhS2r8RfTtpEL2siVwBEzW6LoAAdnkMrgblXoMSRGiaw2sFVGuDUSARzhmVEUz72WbY3-l30eW2WHoaJiCcYxKY_7DS1w1zCGMeiy1pId7Q5Ab3miP55HuJRy6FR3Hkj__jvU_Qzbi0MTDAcA_tLGZL-xSiukXaRtt8xOEoulEb7XYOjr-etMs_JO3SiOF40jn_Bd3sShk
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3bbtMw1BpDAl4QdwoDDAIBgmhJ7Dj2A0KjY2pZu0rQTXszjmOXSiUpTSvoT_GNHOdSFiH2tj5F9Ulan_uJzwWh534SKx0aiE1orD2aCuYpE1GPc6s1ocTqxL0aGB6x3jH9dBqdbqHfTS2MS6tsdGKpqNNcu3fku2EMH0ZFwN_Pf3huapQ7XW1GaFRscWjWPyFkK97194G-L8Lw4OO42_PqqQKeZkwsPRtDPMjB0MecKKHcMDNBVZCC52yZT8BFV8S3msIP-mlEbRglcWCTMDGp8rlVBJ57CV2mBETTVaZ3NyklAVhb0RTmcLZbgO6PhQdW0Sv9Mo-3jF85I-BfS3DGFLbTNM_YvYMb6HrtsOK9isNuoi2T3UJXhvWR_G0070Ek684sphrnv9bAj7iq6Vpj8IfxLM8muDs66e_jV73R2Bvk3dHrt1hl2DWqWEy_40JZs1zj6vACu3IXrDBY0DQHFjQprpPpZ3BZjhi5g44vBOF30XaWZ-Y-wkQkAU8A1HKwqoRykqYJFUpHmqchizsoaPArdd3j3I3amMky1uFMVjSRQBNZ0kTyDnqzuWdedfg4F_qDI9sG0nXnLr_IFxNZC7s0UaBiX3CfKHDvjE2UsaGxAexU0USoDnrmiC5d_43MJfhM1KooZH90IvdgV-BWQZj8P6Avn1tAL2sgm8NGtaqLKgBdrq9XC3KnBQkk1O3lhgFlrcUK-VfmOujpZtnd6TLzMpOvHAzj4CIyAci_V_HrBjmEMdffLeqguMXJLey1V7Lpt7LHueCuM2T84Py_9QRd7Y2HAznoHx0-RNfCUtQC0Pw7aHu5WJlH4DAuk8ellGL09aLVwh-JlHi_
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hyperbaric+oxygen+therapy+for+long+COVID+%28HOT-LoCO%29%2C+an+interim+safety+report+from+a+randomised+controlled+trial&rft.jtitle=BMC+infectious+diseases&rft.au=Kjellberg%2C+Anders&rft.au=Hassler%2C+Adrian&rft.au=Bostr%C3%B6m%2C+Emil&rft.au=El+Gharbi%2C+Sara&rft.date=2023-01-20&rft.issn=1471-2334&rft.eissn=1471-2334&rft.volume=23&rft.issue=1&rft.spage=33&rft_id=info:doi/10.1186%2Fs12879-023-08002-8&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon